Medpace (NASDAQ:MEDP) Price Target Raised to $673.00

Key Points

• TD Cowen raised Medpace’s price target to $673 from $492 while maintaining a Hold rating, implying approximately 3.32% upside from the prior close. The analyst consensus remains Hold, with an average target of $628.73.
• Medpace reported quarterly EPS of $4.84, beating expectations of $4.44, while revenue rose 8.5% year over year to $716 million. Shares opened at $651.39 and remain near their 52-week high of $684.52.
• Insiders have been selling shares: CEO August Troendle sold about 49,018 shares for roughly $30.8 million, while insiders sold approximately $208 million worth of stock over the past three months.

Medpace (NASDAQ:MEDP - Get Free Report) had its target price hoisted by equities researchers at TD Cowen from $492.00 to $673.00 in a research note issued to investors on Friday, Benzinga reports. The firm presently has a "hold" rating on the stock. TD Cowen's target price suggests a potential upside of 3.32% from the stock's previous close.

A number of other research analysts also recently weighed in on MEDP. BMO Capital Markets raised their price target on Medpace from $400.00 to $600.00 and gave the company a "market perform" rating in a research note on Friday, July 24th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Royal Bank Of Canada increased their price objective on Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a report on Friday, July 24th. Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Finally, Jefferies Financial Group restated a "hold" rating on shares of Medpace in a report on Monday, September 14th. Three analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $628.73.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $651.39 on Friday. The company's 50-day moving average price is $609.84 and its two-hundred day moving average price is $536.74. Medpace has a one year low of $373.00 and a one year high of $684.52. The stock has a market capitalization of $18.18 billion, a PE ratio of 38.05, a price-to-earnings-growth ratio of 2.96 and a beta of 1.18.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, beating the consensus estimate of $4.44 by $0.40. The company had revenue of $716.00 million during the quarter, compared to analysts' expectations of $714.47 million. Medpace had a return on equity of 104.17% and a net margin of 18.24%. Medpace's revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned $3.86 EPS. On average, analysts anticipate that Medpace will post 17.54 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Medpace news, CEO August Troendle sold 49,018 shares of the company's stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $628.11, for a total value of $30,788,695.98. Following the transaction, the chief executive officer directly owned 433,372 shares in the company, valued at $272,205,286.92. The trade was a 10.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 336,140 shares of company stock worth $208,008,328 over the last three months. Insiders own 20.50% of the company's stock.

Institutional Trading of Medpace

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Novem Group lifted its position in Medpace by 1.0% during the third quarter. Novem Group now owns 2,127 shares of the company's stock worth $1,328,000 after acquiring an additional 22 shares during the last quarter. Fifth Third Wealth Advisors LLC lifted its holdings in Medpace by 3.2% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 783 shares of the company's stock worth $489,000 after purchasing an additional 24 shares during the last quarter. Balefire LLC increased its position in Medpace by 6.1% during the 1st quarter. Balefire LLC now owns 451 shares of the company's stock worth $217,000 after buying an additional 26 shares during the period. Root Financial Partners LLC increased its position in Medpace by 34.1% during the 1st quarter. Root Financial Partners LLC now owns 122 shares of the company's stock worth $59,000 after buying an additional 31 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Medpace by 2.8% during the second quarter. GAMMA Investing LLC now owns 1,158 shares of the company's stock worth $613,000 after buying an additional 32 shares in the last quarter. Institutional investors own 77.98% of the company's stock.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Raised 2026 outlook: Medpace now expects full-year EPS of $17.97–$18.32, above the $17.68 analyst consensus. Revenue guidance of $2.8–$2.9 billion is also at or above expectations. Medpace forecasts 2026 EPS and buyback
• Positive Sentiment: Quarterly results exceeded expectations: Third-quarter EPS was $4.84 versus the $4.44 consensus, while revenue rose 8.5% year over year to $716 million, slightly ahead of forecasts. Net margin was 18.24%. Medpace third-quarter 2026 results
• Positive Sentiment: Demand indicators remained healthy: Third-quarter net new business awards reached $873 million, and ending backlog grew 5.6% year over year to $3.2 billion, supporting future revenue visibility. Medpace three key takeaways
• Positive Sentiment: $1 billion buyback: The new authorization replaces the prior program and signals management confidence while potentially supporting per-share results. Medpace buyback and third-quarter profit
• Neutral Sentiment: Deutsche Bank raised its price target to $650 from $535 but retained a Hold rating, indicating improved fundamentals may already be reflected in the share price. Deutsche Bank Medpace price target
• Negative Sentiment: Investors remain concerned that Medpace is expensive, with commentary suggesting the stock may be about 24% overvalued. Those concerns help explain why the shares decreased even after the earnings beat and raised outlook. Medpace valuation analysis

About Medpace

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace's services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.